Infantile Bullous Pemphigoid and Linear IgA Bullous Disease Presenting as Hand‐Foot‐and‐Mouth Disease With Positive Enterovirus PCR

Anthony J. Mancini has served as a consultant for Verrica, Alphyn, Galderma, and Pelthos and has served on the speakers bureau for Verrica. Amy S. Paller has served as an investigator for AbbVie, Biomendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, MoonLake, Quoin, Regeneron, TWI, and UCB; as a consultant for Abeona, Almirall, Apogee, APR Applied Pharma Res, Arcutis, BioCryst, Boehringer Ingelheim, Chiesi, Gedeon Richter, Johnson & Johnson Innovative Medicine, Kamari, Lilly, L'Oréal, MoonLake Immunotherapeutics, Novartis, Palvella, Pelthos, Pfizer, Quoin, Sanofi, and Takeda; and has served on data safety monitoring boards for AbbVie, Abeona, BioCryst, and Galderma. The remaining authors declare no conflicts of interest. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.